MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Canada, Australia, and New Zealand. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. Its LSD-microdosing is currently under Phase 2 clinical trials for the treatment of major depressive disorder and microdosing of LSD in late-stage cancer patients. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.011472375162019922 | N/A |
Market Cap | $1.26M | N/A |
Shares Outstanding | 110.14M | -17.22% |
Employees | 0 | N/A |
Shareholder Equity | -5.42M | 28.24% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.29 | N/A |
P/B Ratio | -0.23 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.4944 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$2.68M | N/A |
EPS | -0.0389 | N/A |
Earnings Yield | -3.39 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $420.65K | N/A |
Total Debt | $3.11M | N/A |
Cash on Hand | $208.82K | N/A |
Debt to Equity | -0.7027 | -18.66% |
Cash to Debt | 0.0672 | N/A |
Current Ratio | 0.2300 | -82.99% |